Between May 29th and June 2nd, 2026, clinicians and researchers from around the world gathered in Chicago, IL for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The […]
Updated NCCN Guidelines for Patients Reflect the Latest Advances in Pancreatic Cancer Care
The latest edition of the NCCN Guidelines for Patients: Pancreatic Cancer is now available, providing patients and caregivers with updated information to help them better understand treatment options, ask informed […]
Predicting pancreatic cancer risk in high-risk acute pancreatitis patients
Pancreatitis or inflammation of the pancreas comes in both acute and chronic forms and has long been appreciated as a risk factor for developing pancreatic cancer. While common and in […]
Daraxonrasib, a game changer for pancreatic cancer patients
The wait is over. On Sunday May 31st 2026, Brian M Wolpin MD, MPH, the Director of the Hale Family Center for Pancreatic Cancer Research at Dana Farber Cancer Institute, […]
Innovative Glycoengineering Strategy Could Reveal New Biomarkers for Pancreatic Cancer
While the 5-year survival rate for pancreatic cancer has increased over the last decade to 13%, it continues to be one of the toughest cancers to diagnose and treat. One […]
FDA Expands Access to Daraxonrasib: What Patients Need to Know
The FDA has granted permission for Revolution Medicines to provide access to its investigational RAS inhibitor, daraxonrasib, through an Expanded Access Program (EAP) for certain patients with metastatic pancreatic ductal […]